世界の感染症ワクチンにおける提携条件と契約（2016年～2023年）：取引動向、参入企業、財務情報

目次

エグゼクティブサマリー

第1章 イントロダクション

第2章 感染症ワクチンにおける取引動向

• イントロダクション
• 長年にわたって提携している感染症ワクチン
• 最も活躍する感染症ワクチンの取引業者
• 感染症ワクチンにおける提携、取引タイプ別
• 感染症ワクチンにおける提携、治療領域別
• 感染症ワクチンにおける提携の契約条件

第3章 主要な感染症ワクチンにおける取引

第4章 最も活躍する感染症ワクチンにおける取引業者

• イントロダクション
• 最も活躍する感染症ワクチンの取引業者
• 最も活躍する感染症ワクチン提携企業プロファイル

第5章 感染症ワクチンにおける取引ディレクトリ

第6章 感染症ワクチンにおける取引、技術タイプ別

付録

Wildwood Venturesについて

Description

Infectious Vaccine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the infectious vaccine deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of infectious vaccine deals from 2016 to 2023.

The report provides a detailed understanding and analysis of how and why companies enter infectious vaccine deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 484 infectious vaccine deals announced since 2016 including financial terms where available including links to online deal records of actual infectious vaccine partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of infectious vaccine dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in infectious vaccine dealmaking since 2016.

Chapter 3 provides an overview of the leading infectious vaccine deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in infectious vaccine dealmaking with a brief summary followed by a comprehensive listing of infectious vaccine deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of infectious vaccine deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of infectious vaccine partnering deals signed and announced since Jan 2016. The chapter is organized by specific infectious vaccine technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in infectious vaccine deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Infectious Vaccine Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse infectious vaccine collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Infectious Vaccine Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of infectious vaccine trends and structure of deals entered into by leading biopharma companies worldwide.

Infectious Vaccine Collaboration and Licensing Deals includes:

• Trends in infectious vaccine dealmaking in the biopharma industry
• Directory of infectious vaccine deal records covering pharmaceutical and biotechnology
• The leading infectious vaccine deals by value
• Most active infectious vaccine licensing dealmakers
• Infectious Vaccine Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Benefits

Infectious Vaccine Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse infectious vaccine collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in infectious vaccine dealmaking

• 2.1. Introduction
• 2.2. Infectious vaccine deals over the years
• 2.3. Most active infectious vaccine dealmakers
• 2.4. Infectious vaccine deals by deal type
• 2.5. Infectious vaccine deals by therapy area
• 2.6. Infectious vaccine deals by industry sector
• 2.7. Deal terms for infectious vaccine deals
  • 2.7.1 Infectious vaccine deals headline values
  • 2.7.2 Infectious vaccine deal upfront payments
  • 2.7.3 Infectious vaccine deal milestone payments
  • 2.7.4 Infectious vaccine royalty rates

Chapter 3 - Leading infectious vaccine deals

• 3.1. Introduction
• 3.2. Top infectious vaccine deals by value

Chapter 4 - Most active infectious vaccine dealmakers

• 4.1. Introduction
• 4.2. Most active infectious vaccine dealmakers
• 4.3. Most active infectious vaccine deals company profiles

Chapter 5 - Infectious vaccine contracts dealmaking directory

• 5.1. Introduction
• 5.2. Infectious vaccine contracts dealmaking directory

Chapter 6 - Infectious vaccine dealmaking by technology type

• Deal directory
• Deal directory - Infectious vaccine deals by company A-Z
• Deal directory - Infectious vaccine deals by deal type
• Deal directory - Infectious vaccine deals by therapy area
• Deal type definitions
• About Wildwood Ventures
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering
•  

Table of figures

• Figure 1: Infectious vaccine deals since 2016
• Figure 2: Active infectious vaccine dealmaking activity - 2016 - 2023
• Figure 3: Infectious vaccine deals by deal type since 2016
• Figure 4: Infectious vaccine deals by therapy area since 2016
• Figure 5: Infectious vaccine deals by industry sector since 2016
• Figure 6: Infectious vaccine deals with a headline value
• Figure 7: Infectious vaccine deals with an upfront value
• Figure 8: Infectious vaccine deals with a milestone value
• Figure 9: Infectious vaccine deals with a royalty rate value
• Figure 10: Top infectious vaccine deals by value since 2016
• Figure 11: Most active infectious vaccine dealmakers 2016 - 2023
• Figure 12: Infectious vaccine deals by technology type since 2016